Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
69 hedge funds and large institutions have $184M invested in Marinus Pharmaceuticals, Inc in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 16 closing their positions.
218% more call options, than puts
Call options by funds: $4.72M | Put options by funds: $1.49M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
33% more capital invested
Capital invested by funds: $139M → $184M (+$45.6M)
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
5% less funds holding
Funds holding: 73 → 69 (-4)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$8.42M |
| 2 |
AC
Antara Capital
New York
|
+$3.26M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.59M |
| 4 |
Walleye Capital
New York
|
+$1.77M |
| 5 |
Goldman Sachs
New York
|
+$477K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$5.69M |
| 2 |
AG
Artal Group
Luxembourg
|
-$5.19M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.17M |
| 4 |
Millennium Management
New York
|
-$1.07M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$551K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Jane Street
New York
| – | -$68K | -14,078 | Closed |
|
|
CG
77
Cutler Group
San Francisco,
California
| – | -$64K | -13,259 | Closed |
|
|
VRM
78
Vectors Research Management
New York
| – | -$10K | -2,000 | Closed |
|
79
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -260 | Closed |
|
80
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$31 | +5 | +11% |
|
MRNS Hedge Fund Activity: Q3 2022 in Review
69 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2022, worth a combined $184M — up 33% from $139M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of MRNS and 12 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 20 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $8.42M. The largest seller was 683 Capital Management, cutting an estimated $5.69M.
- 69 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2022, down from 73 in Q2 2022.
- Funds reported $184M of Marinus Pharmaceuticals, Inc stock for Q3 2022, up 33% quarter-over-quarter.
- 12 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2022 and 16 closed out, a net change of -4 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2022 was Woodline Partners, an estimated $8.42M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2022 was 683 Capital Management, an estimated $5.69M sold.
Based on aggregated 13F filings for Q3 2022.